MorphoSys Presents Preliminary Results from Phase 1/2 Study

EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potential Application in a Broad Array of Advanced Tumors 27.10.2022 / 22:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media Re...

Related Keywords

Germany , United States , Planegg , Bayern , Massachusetts , Washington , Boston , Sweden , Spain , Barcelona , Comunidad Autonoma De Cataluna , Swedish , American , Thomas Biegi , Tim Demuth , Julia Neugebauer , Eamonn Nolan , Charles Drescher , Gynecologic Cancer Research , Swedish Cancer Institute In Seattle , Development Officer , Linkedin , National Cancer Institute , Twitter , European Organisation For Research , Nasdaq , Distribution Services , Exchange Commission , American Association For Cancer Research , Sys Presents Preliminary Results , Supporting Its Potential Application , Broad Array , Advanced Tumors , Molecular Targets , Cancer Therapeutics , European Organisation , American Association , Cancer Research , Gynecologic Oncologist , Medical Director , Swedish Cancer Institute , Morphosys Chief Research , Morphosy Annual Report , Corporate News , Regulatory Announcements ,